Patents
Literature
Patsnap Eureka AI that helps you search prior art, draft patents, and assess FTO risks, powered by patent and scientific literature data.

16974results about "Hybrid peptides" patented technology

Muscle targeting complexes and formulations for treating dystrophinopathies

Aspects of the disclosure relate to complexes and other aspects relate to formulations (e.g., aqueous, lyophilized forms) comprising such complexes (e.g., wherein each complex is of the exemplary formula shown below) comprising a phosphorodiamidate morpholino oligomer (e.g., useful for targeting DMD) covalently linked to an antibody (e.g., anti-TfR1 antibody). In some embodiments, the complexes are formulated with histidine (e.g., L-histidine) and sucrose at a specified pH (e.g., about 5.0 to 7.0). Also provided are uses of these formulations for treating a subject having a mutated DMD allele associated with Duchenne Muscular Dystrophy.
Owner:DYNE THERAPEUTICS INC

Dosing of muscle targeting complexes for treating dystrophinopathies

Aspects of the disclosure relate to methods of promoting expression or activity of a dystrophin protein and / or methods of treating DMD in a subject. In some embodiments, the methods comprise administering to the subject a composition comprising complexes (e.g., muscle targeting complexes) comprising a phosphorodiamidate morpholino oligomer (e.g., useful for targeting DMD) covalently linked to an antibody (e.g., anti-TfR1 antibody).
Owner:DYNE THERAPEUTICS INC

GLP-1R and GCGR double-target-activated polypeptide or derivative thereof, pharmaceutically acceptable salt and application of polypeptide or derivative and pharmaceutically acceptable salt

The invention provides a polypeptide or a derivative and a pharmaceutically acceptable salt thereof. The amino acid sequence of the polypeptide is as shown in SEQ ID NO: 1. The polypeptide or the derivative and the pharmaceutically acceptable salt thereof disclosed by the invention can be combined with GLP-1R and GCGR, and is used for effectively activating the GLP-1R and the GCGR. Therefore, the polypeptide or the derivative and the pharmaceutically acceptable salt thereof can be used for detecting GLP-1R and / or GCGR, and can also be used for treating or preventing GLP-1R and / or GCGR related diseases (such as metabolic disorder related diseases, such as obesity, diabetes, fatty liver diseases, non-alcoholic fatty liver diseases and the like).
Owner:TENCENT TECHNOLOGY (SHENZHEN) CO LTD

Ras-gtpase inhibitor and use thereof to treat oncological diseases

PCT designated stage expiredWO2025127968A2Peptide/protein ingredientsDepsipeptidesDiseaseOncology
The invention relates to the field of biotechnology and medicine, and more particularly to a polypeptide having the amino acid sequence SEQ ID NO: 1 and being capable of inhibiting RAS-GTPase activity, to the use of said polypeptide to produce a drug for treating stomach cancer or rectal cancer in a dose of 0.81-3.00 mg / kg, as well as to a drug based on said polypeptide for the treatment of stomach cancer or rectal cancer, and to a method for treating stomach cancer or rectal cancer by intraperitoneally administering said drug to a subject in an amount of 150 ml twice at an interval of 7 days.
Owner:FEDERALNOE GOSUDARSTVENNOE BJUDZHETNOE UCHREZHDENIE ROSSIJSKIJ NAUCHNYJ TSENTR RENTGENORADIOLOGII MINISTSTVA ZDRAVOOKHRANENIJA ROSSIJSKOJ FEDERATSII (FGBU RNTSRR MINZDRAVA ROSSII)

Anti-human serum albumin nano antibody and application thereof

The invention provides an anti-human serum albumin nano antibody and application thereof, and belongs to the technical field of antibodies. The invention provides an anti-human serum albumin nano antibody HSA-32 with relatively high affinity, and the anti-human serum albumin nano antibody HSA-32 is subjected to humanized transformation, so that three obtained humanized anti-human serum albumin nano antibodies can be used for reducing the immunogenicity of the HSA-32 and improving the immunogenicity of the HSA-32; and high specificity and high affinity of combination with the human serum albumin and stability and solubility of the antibody are maintained. The anti-human serum albumin nano antibody can be used for separation, purification and detection of human serum albumin and separation and purification of polypeptide, protein or antibody drugs fused with the anti-human serum albumin nano antibody. Meanwhile, the anti-human serum albumin nano-antibody can effectively prolong the half-life period of polypeptide, protein and antibody drugs fused with the anti-human serum albumin nano-antibody, and can be used for developing long-acting polypeptide, protein or antibody drugs.
Owner:INST OF ZOOLOGY CHINESE ACAD OF SCI

Compositions and methods for treating neurocognitive disorders

To provide methods for treating a subject having or at risk of developing a neurocognitive disorder, such as frontotemporal lobar degeneration or neuronal ceroid lipofuscinosis.SOLUTION: Provided is a method comprising administering, to a subject diagnosed as having a neurocognitive disorder (NCD), a composition comprising a population of cells comprising a transgene encoding a progranulin (PGRN) or a granulin (GRN).SELECTED DRAWING: Figure 1A
Owner:AVROBIO INC

Recombinant humanized type iii collagen and preparation method therefor

A recombinant humanized collagen and a preparation method therefor. The recombinant humanized type III collagen can be efficiently and stably expressed in three expression systems of yeast, Escherichia coli, and CHO cells, and has the biological activity superior to that of a commercially available collagen product. The recombinant humanized type III collagen has structural characteristics and functional activity similar to those of a natural collagen, and thus has wide application prospects in biomedical materials, tissue engineering products, cosmetics, foods, health care products or drugs, medical instruments, medical cosmetology and the like.
Owner:YANTAI PATRONUS BIOTECH CO LTD +1

Nanobody Targeting Human Serum Albumin and Its Application

The present invention discloses a human serum albumin-targeting nanobody and its application. A variety of human serum albumin-targeting nanobodies that can be used to construct long-acting fusion protein drugs and their immune screening methods are disclosed. The antibody is composed only of the heavy chain variable region and can be fused and expressed with therapeutic proteins or polypeptide drugs such as interleukin, interferon, and tumor necrosis factor in an Escherichia coli expression system. The fusion protein has the activity of specifically binding to human serum albumin, has a relatively high affinity, can effectively extend the drug half-life, and does not affect the biological activity of the recombinant protein drug at the same time.
Owner:CHANGCHUN INST OF BIOLOGICAL PRODS

Recombinant mussel-like mucin (type III), nucleic acid molecule, fermentation strain, preparation method and application

The invention belongs to the technical field of biology, and discloses a recombinant mussel-like mucin (type III), a nucleic acid molecule, a fermentation strain, a preparation method and application. The recombinant mussel-like adhesive protein provided by the invention comprises a type III mussel adhesive protein and a biological functional peptide fragment (as shown in SEQ ID NO: 1, 5 and / or 8) which are connected through a peptide bond. According to the recombinant mussel-like mucin, biological functional peptide is introduced, and common engineering bacteria such as escherichia coli and the like can be directly subjected to dopa doping expression in cells by utilizing dopa, so that the recombinant mussel-like mucin with high dopa content is obtained; the problem that the biological safety is reduced due to the introduction of tyrosinase in the existing mussel mucoprotein preparation can be effectively solved; meanwhile, the recombinant mussel mucoprotein has good biological activities of promoting cell migration, scavenging free radicals, resisting inflammation, inhibiting bacteria, inhibiting tyrosinase, soothing skin and the like, has huge potential of serving as a skin repair active component, and can be well applied to the field of medical treatment and / or cosmetics.
Owner:XIAMEN AISTRONDA MEDICAL TECHNOLOGY CO LTD

Bovine serum albumin combined nano antibody and application thereof

The invention discloses a bovine serum albumin combined nano antibody and a preparation method and application thereof, the amino acid sequence of the bovine serum albumin combined nano antibody Nb1 is shown as SEQ.ID No.1, the nano antibody Nb not only has high affinity to bovine serum albumin, but also has good binding activity to both human serum albumin and mouse serum albumin, and the nano antibody Nb has high affinity to human serum albumin and mouse serum albumin. And the antibody has a relatively good broad-spectrum application range, and can be widely applied to the aspects of drug half-life period enhancement, tumor targeted therapy and imaging, immunodetection or diagnosis, recombinant albumin purification or enrichment and the like.
Owner:SHANGHAI XINRUITE BIOMEDICAL TECH

Methods and compositions for treating myotonic dystrophy

PCT designated stage expiredWO2025147541A1Genetic material ingredientsMuscular disorderAntiendomysial antibodiesSwallowing impairment
Aspects of the disclosure relate to methods of reducing fatigue in a subject having myotonic dystrophy type 1 (DM1). Aspects of the disclosure relate to methods of treating one or more symptoms assessable by the MDHI (e.g., a GI symptom, myotonia, upper extremity function impairment, fatigue, mobility impairment, impairment in the ability to perform activities, pain, vision impairment, communication impairment, sleep impairment, emotional issues, cognitive impairment, social satisfaction impairment, social performance impairment, breathing impairment, swallowing impairment, and / or hearing impairment) in a subject having myotonic dystrophy type 1 (DM1). In some embodiments, the methods comprise administering to the subject a composition comprising complexes (e.g., muscle targeting complexes) comprising an oligonucleotide (e.g., a DMPK- targeting oligonucleotide) covalently linked to an antibody (e.g., anti-TfRl antibody).
Owner:DYNE THERAPEUTICS INC

Recombinant human III-type collagen with triple-helix structure and assembled into collagenous fiber and application of recombinant human III-type collagen

The invention provides recombinant human III-type collagen which is of a triple-helix structure and assembled into collagenous fibers and application of the recombinant human III-type collagen, and belongs to the technical field of bioengineering. Collagen fragments capable of forming a triple helix structure are screened out through a bioinformatics algorithm, the fragments are connected in series, a key C-terminal structural domain and a specific amino acid sequence are combined, and formation of a stable triple helix advanced structure and assembly of collagenous fibers are effectively promoted. The recombinant human III type collagen is efficiently expressed through a eukaryotic expression system, and shows excellent stability, low immunogenicity and good biocompatibility. Experimental results show that the prepared recombinant human III-type collagen not only has a natural triple helix structure, but also can be further assembled into macromolecular collagen fibers, is suitable for multiple fields such as medical beauty, bioengineering and tissue repair, and has wide application prospects and market values.
Owner:CHANGCHUN PUMAIFU BIOTECHNOLOGY CO LTD

Targeting IL-6 nano antibody and application thereof

The invention belongs to the technical field of immunology, and particularly relates to a targeted IL-6 biological nano antibody and application thereof. The invention discloses a nano antibody for targeting IL-6, which comprises a heavy chain variable region containing CDR1, CDR2 and CDR3, and has the functions of identifying and combining IL-6. The invention also discloses a composition containing the nano antibody or the IL-6 binding molecule, and an application of the composition containing the nano antibody and the IL-6 binding molecule in preparation of drugs for treating IL-6 related diseases. The nano antibody, the BCMA binding molecule and the composition can recognize and bind IL-6, and have a potential effect of treating IL-6 related diseases.
Owner:DONGGUAN SOUTHEAST CENTRAL HOSPITAL (DONGGUAN SOUTHEAST TRADITIONAL CHINESE MEDICINE MEDICAL SERVICE CENTER DONGGUAN FIRST HOSPITAL AFFILIATED TO GUANGDONG MEDICAL UNIVERSITY)

Recombinant humanized XVII type collagen as well as expression vector and genetically engineered bacterium thereof

The invention discloses a recombinant humanized XVII type collagen as well as an expression vector and a genetically engineered bacterium thereof. Four functional fragments with high activity are obtained through screening, one of the fragments is optimized and then combined according to a certain sequence to obtain recombinant humanized XVII type collagen JYC1703, or one of the fragments is optimized and then combined according to a certain sequence, and GPP sequences are fused at an amino terminal and a carboxyl terminal respectively to obtain recombinant humanized XVII type collagen JYC1701 and JYC1702, and the recombinant humanized XVII type collagen JYC1701 and JYC1702 are combined according to a certain sequence to obtain the recombinant humanized XVII type collagen JYC1701 and JYC1702. After codon optimization, amplifying and cloning into an expression vector, transforming into pichia pastoris competent cells after enzyme digestion linearization, and screening high-copy recombinants through G418 resistance gradient, so as to obtain pichia pastoris genetically engineered bacteria for expressing recombinant humanized XVII type collagen. The recombinant humanized XVII type collagen JYC1701, JYC1702 and JYC1703 disclosed by the invention show excellent functions of promoting cell adhesion, cell proliferation and cell migration, and are suitable for preparing products such as skin care products or medical instruments and the like.
Owner:ZHEJIANG ZHUJI JUYUAN BIOTECHNOLOGY CO LTD

Polypeptide and application thereof in preparation of medicine for preventing and / or treating cancer

The invention discloses a polypeptide and application thereof in preparation of a medicine for preventing and / or treating cancers. The amino acid sequence of the polypeptide is shown as SEQ ID No. 1 or SEQ ID No. 2. The cancer is at least one of breast cancer, colorectal cancer, leukemia, esophageal cancer, pancreatic cancer, brain glioma, kidney cancer, skin cancer, osteosarcoma, ovarian cancer and prostate cancer. The invention designs and synthesizes the polypeptide of a targeted staphylococcus tumor protein compound SND1-MTDH containing a nuclease structural domain 1 (SND1 and a heteromucin (MTDH), finds that the polypeptide has excellent inhibitory activity on various different types of human cancer cells for the first time, and provides an optional scheme for broad-spectrum anti-cancer drugs. The polypeptide applied in the invention is simple in synthesis process and low in production cost.
Owner:KUNMING MEDICAL UNIVERSITY

Recombinant fragmented human-derived III-type collagen as well as preparation method and application thereof

The invention discloses recombinant fragmented human III-type collagen as well as a preparation method and application thereof. The amino acid sequence of the recombinant fragmented human III-type collagen is shown as SEQ ID NO.3, and the recombinant fragmented human III-type collagen does not contain propeptides but comprises terminal peptides necessary for fiber formation; the coding gene is obtained by splicing and recombining human III type collagen amino acid sequence fragments with amino acid sequences as shown in SEQ ID NO.1 and SEQ ID NO.2, and the nucleotide sequence of the coding gene is as shown in SEQ ID NO.4. According to the method, rapid purification can be carried out, and the purified collagen is non-toxic to cells.
Owner:WUZHONG AESTHETIC BIOTECHNOLOGY (SHANGHAI) CO LTD

Cas enzyme and system and use thereof

The present application relates to the field of biomedicine, and specifically relates to a novel Cas enzyme, a system thereof and the use thereof.
Owner:EPIGENIC THERAPEUTICS PTE LTD

Recombinant herpes zoster vaccine as well as preparation method and application thereof

ActiveCN119386170Ahigh titerstrong immune responseAntibody mimetics/scaffoldsViral antigen ingredientsHerpes zoster virusHerpes Zoster Vaccine
The invention discloses a recombinant herpes zoster vaccine as well as a preparation method and application thereof, and particularly relates to the technical field of biological medicines. The recombinant herpes zoster vaccine comprises a recombinant herpes zoster vaccine fusion protein purified product HN101 and a liposome mixture HA201, and the recombinant herpes zoster fusion protein gE-gD is constructed by recombining reconstructed gE protein and reconstructed gD protein. The gE-gD recombinant herpes zoster fusion protein is obtained by reconstructing gE protein of varicella-herpes zoster virus and gD protein of HSV through a gene recombination technology and then recombining the gE protein and the gD protein. After the gE-gD recombinant herpes zoster fusion protein is combined with a liposome mixture HA201, stronger immune response can be induced, the antibody titer and cellular immunity are improved, the vaccine effect is enhanced, and meanwhile, the potential infection risk is avoided.
Owner:JIANGSU WALVAX BIOTECHNOLOGY CO LTD

Protein purification method

The present invention relates to a method for the production and purification of a protein of interest, and more particularly, the present invention relates to a fusion protein comprising: a self-aggregating peptide, a linker peptide comprising an amino acid sequence selected from an elastin-like polypeptide (ELP) or a protease propeptide (ProP) and the spacer comprising a cleavage site, and a protein portion of interest, and a method for column-free one-step purification of a target protein by expressing the fusion protein.
Owner:GUANGZHOU NOVI SYNTHETIC BIOTECHNOLOGY CO LTD

Fusion protein and application thereof in preparation of Brazilian sweet

The invention provides a fusion protein and application thereof in preparation of Brazilian sweet. The fusion protein comprises a tag protein and a Brazilian sweet protein which are connected by a linker; wherein the linker comprises an amino acid sequence as shown in SEQ ID NO: 1, and the amino acid sequence as shown in SEQ ID NO: 1 is directly connected with the Brazilian sweet protein. The invention also provides a preparation method of the Brazilian sweet protein. The preparation method comprises the following steps: treating the fusion protein by using TEV protease and obtaining the Brazilian sweet protein. Large-scale expression of the fusion protein and the brazitame protein is realized by utilizing an escherichia coli expression system, and the obtained brazitame protein can be correctly folded and has high sweetness.
Owner:HANGZHOU YANSHOU TECHNOLOGY CO LTD

Varicella-zoster virus gE fusion protein as well as preparation method and application thereof

The invention belongs to the field of biological medicines, and particularly relates to a varicella-zoster virus gE fusion protein as well as a preparation method and application thereof. The varicella-zoster virus gE fusion protein comprises an amino acid sequence as shown in SEQ ID NO: 1 and at least one of the following fragments: a signal peptide, a Foldon sequence, a Ferritin sequence and a His tag sequence, the signal peptide can improve the protein expression quantity, the Foldon sequence can improve the stability of the protein, the particle size of an antigen can be increased, the immunogenicity of the antigen can be improved, and the fusion protein can be used for preparing a medicine for treating the varicella-zoster virus gE fusion protein. The Ferritin sequence can enhance immune response, a vaccine prepared from the gE fusion protein has excellent immunogenicity, and compared with a commercially available vaccine Shingrix, higher humoral immunity and cellular immunity levels can be induced.
Owner:BEIJING HUANUOTAI BIOMEDICAL TECH CO LTD

A method for preparing GLP-1 or its analogs

The present invention belongs to the field of biopharmaceutical technology, and specifically relates to a method for preparing GLP-1 or its analogs. The present invention provides a leader peptide, and a fusion protein comprising the leader peptide. The leader peptide or fusion protein is used to prepare a semaglutide precursor polypeptide, and the results show that the yield of the prokaryotic expression fusion protein can reach 26g / L, and the purity of the precursor polypeptide obtained after enzyme cleavage is higher than 95%. The precursor polypeptide is further side-chain modified and connected with a dipeptide to efficiently prepare semaglutide.
Owner:HANPEPTIDE BIOPHARMACEUTICAL GRP CO LTD

Biosynthetic recombinant human fibronectin and preparation method

Provided are a biosynthetic recombinant human fibronectin and a preparation method. The polypeptide of the present disclosure comprises an amino acid sequence as shown in SEQ ID NO: 1. The polypeptide is a natural polypeptide derived from human fibronectin, can be used as fibronectin for medical instruments, and has wide prospects for application in beautification such as wrinkle removal, spot fading and whitening and medical fields such as tumor treatment, anti-infection, and skin wound repair.
Owner:SHANXI JINBO BIO PHARMACEUTICAL CO LTD

Cas12i3-based fusion protein and application thereof in mediating gene editing

The invention relates to a fusion protein based on Cas12i3 and application of the fusion protein in mediating gene editing, the fusion protein is formed by fusing NLSSV 40, Cas12i3, NLS, IEE and XTEN, the amino acid sequence of the NLSSV 40 is shown as SEQ ID No. 3, the amino acid sequence of the Cas12i3 is shown as SEQ ID No. 5, the amino acid sequence of the NLS is shown as SEQ ID No. 7, the amino acid sequence of the IEE is shown as SEQ ID No. 9, and the amino acid sequence of the XTEN is shown as SEQ ID No. 11.
Owner:INST OF PLANT PROTECTION CHINESE ACAD OF AGRI SCI

Fusion protein and application thereof in preparation of precursor polypeptide of semeglutide

The invention discloses a fusion protein and application thereof in preparation of a semeglutide precursor polypeptide, N (N is greater than or equal to 1) semeglutide fragments GLP-1 (11-37) are connected through KR, and then the semeglutide fragments GLP-1 (11-37), enterokinase enzyme cutting sites and fusion protein tags are subjected to fusion tandem expression in sequence, so that the semeglutide precursor polypeptide is obtained. The obtained fusion protein is a fusion protein tag-restriction enzyme cutting site-N-linked semeglutide fragment GLP-1 (11-37), and the fusion protein tag is an albumin affinity peptide (SEQ ID NO.1). The fusion protein is subjected to competent heterologous expression in escherichia coli BL21 (DE3), an engineering strain is constructed, and then fermentation expression is performed by using a shake flask, so that the thallus fermentation density is greatly improved, the expression of a target protein in an inclusion body is promoted, the yield of the target protein is improved, and the method has a good industrial application prospect. The fusion protein can be further successfully recognized by commercial enterokinase, KEX2 enzyme and carboxypeptidase B and cut to release the precursor polypeptide of the semeglutide.
Owner:JIANGNAN UNIV

Bovine I-type alpha interferon-ferritin fusion protein, and mutant, preparation method and application of bovine I-type alpha interferon-ferritin fusion protein

The invention discloses a bovine I-type alpha interferon-ferritin fusion protein, a mutant thereof, a preparation method and an application of the bovine I-type alpha interferon-ferritin fusion protein. The bovine I-type alpha interferon is fused with a ferritin subunit, and interferon molecules are highly repeatedly and orderly displayed on the surface of a ferritin nanocage by utilizing the self-assembly characteristic of ferritin, so that the expression level, the structural stability and the antiviral activity of the interferon are remarkably improved. The fusion protein is further subjected to single-site or multi-site rational design mutation, and a mutant with significantly improved antiviral activity and stability is obtained. According to the invention, a silkworm or insect cell eukaryotic expression system is adopted to express the fusion protein or the mutant thereof, and the expression system is safe to operate, simple and convenient in procedure, low in cost and extremely beneficial to large-scale industrial production; the prepared fusion protein or mutant nanoparticles have application prospects in preparation of drugs or reagents for preventing or treating bovine viral diseases.
Owner:THE INST OF BIOTECHNOLOGY OF THE CHINESE ACAD OF AGRI SCI

Anti-p-Tau217 protein monoclonal antibody as well as preparation method and application thereof

The invention provides a monoclonal antibody of a p-Tau217 protein and an application of the monoclonal antibody. In particular, the present invention provides an antibody or an antigen binding fragment thereof targeting a p-Tau217 protein. The antibody provided by the invention can specifically recognize and bind the p-Tau217 protein, does not recognize p-Tau181 and non-phosphorylated Tau protein, and can be used for preparing a detection preparation or a kit for diagnosing diseases related to the p-Tau217 protein, such as Alzheimer's disease.
Owner:SHANGHAI BIOGERM MEDICAL TECH CO LTD +1

Long-acting cat omega 2 interferon recombinant protein FeIFN-omega 2-Fc and application

The invention belongs to the field of interferon gene engineering, and discloses a long-acting cat omega2 interferon recombinant protein FeIFN-omega2-Fc and application, and the FeIFN-omega2-Fc provided by the invention has the characteristics of high activity, obvious antiviral effect and long half-life period. The applicant carries out effective fusion and mutation on the basis of omega2 interferon, and finally obtains the recombinant protein FeIFN-omega2-Fc. The protein obviously activates downstream signal factors of interferon, has the effect of resisting various cat viruses, shows good safety and curative effect when cat herpes treatment experiments are carried out on cats, and compared with FeIFN-omega2, the half-life period of recombinant interferon is obviously prolonged. The FeIFN-omega2-Fc has a good antiviral effect, can effectively prevent and treat cat viral diseases, has a wide application prospect, and particularly has a relatively good popularization potential in clinical treatment.
Owner:HUAZHONG AGRI UNIV

Improved crispr / cas guide RNA (GRNA)

PCT designated stage expiredWO2024231575A1Special deliveryActivity regulationPharmaceutical drugGuide RNA
Modified guide RNAs for EV-mediated delivery of gene editing machinery, complexes, EVs, EV producer cells and pharmaceutical compositions comprising the same, and uses thereof, for example to treat genetic diseases and disorders.
Owner:EVOX THERAPEUTICS LTD